– CHINA, Shanghai – Zai Lab Limited (HKEX: 9688 | NASDAQ: ZLAB), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced the appointment of Dr. Richard Gaynor (M.D.) to its Board of Directors.
“We are pleased to welcome Richard to our Board. Richard is recognized as a leader in the biopharmaceutical industry. His deep experience as an oncologist and his expertise in research and development will be invaluable to Zai as we grow and advance our innovative pipeline to serve patients worldwide,” said Founder Board Chair and CEO, Dr. Samantha Du.
She added: “We have added extensive experience to our Board with the appointments of two new members – Dr. Gaynor and Scott Morrison — in the past two months. We are excited by the collective expertise the Board will bring to Zai Lab as we strengthen our capabilities and execute our global strategy.”
Dr. Gaynor will also join the Research and Development Committee as Chair.
About Dr. Richard Gaynor
Dr. Gaynor is the President and Chief of Research and Development of BioNTech US. Prior to this, he was President, Research and Development, at Neon Therapeutics, beginning in 2016. Previously, Dr. Gaynor spent 15 years in senior roles at Lilly Oncology, including as VP, Clinical Development, and Medical Affairs. He chaired the Lilly Oncology Research and Development Committee and helped oversee collaborations with such companies as Bristol Myers Squibb, Merck, AstraZeneca, and GE Healthcare. Dr. Gaynor also led preclinical and early clinical oncology research at Lilly.
Dr. Gaynor holds an M.D. from the University of Texas Southwestern Medical School, where he served a residency in internal medicine. He completed fellowship training in hematology-oncology at the UCLA School of Medicine, where he spent nine years on the faculty. He then served for 11 years on the faculty at the University of Texas Southwestern Medical School, including as the Chief of Hematology-Oncology and Director of the Simmons Cancer Center. He is the author of nearly 150 publications.
He participates on numerous advisory boards and committees, including currently serving as a Director of Alkermes, Infinity Pharmaceuticals, and the Damon Runyon Cancer Research Foundation.
“It’s an honor to join the Zai Lab Board and to work alongside Samantha and her team in achieving the company’s vision of becoming a global biopharmaceutical company. I look forward to contributing to Zai Lab’s future growth and success as the company executes many late-stage development activities in oncology that have the potential to change patients’ lives in China and around the world,” said Dr. Gaynor.
About Zai Lab
Zai Lab is a patient-focused, innovative, commercial-stage, global biopharmaceutical company focused on developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. To that end, our experienced team has secured partnerships with leading global biopharmaceutical companies to generate a broad pipeline of innovative marketed products and product candidates. We have also built an in-house team with strong product discovery and translational research capabilities and are establishing a pipeline of proprietary product candidates with global rights. Our vision is to become a leading global biopharmaceutical company, discovering, developing, manufacturing, and commercializing our portfolio to impact human health worldwide.
For more information: http://www.zailaboratory.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.